^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Medulloblastoma |
| Drug: | buparlisib (AN2025) (PI3K inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1330 - Novel dual inhibitors of HDAC and PI3Kinase signaling pathways in treatment of p53 driven medulloblastoma
Published date:
03/10/2021
Excerpt:
p53-mutant MB cell line was used to investigate the signaling pathway that regulates proliferation, migration, and drug resistance using inhibitors of HDAC (LBH-589) and PI3K/mTOR [Buparlisib (BKM-120)/rapamycin)]or CUDC-907 (dual inhibitor of HDACs and PI3K/AKT). Results demonstrated that...MB cells displayed strong resistance to BKM-120, whereas LBH-589 or CUDC-907 caused apoptosis...
